<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01105884</url>
  </required_header>
  <id_info>
    <org_study_id>CDS01</org_study_id>
    <nct_id>NCT01105884</nct_id>
  </id_info>
  <brief_title>Clinical and Cost Effectiveness of Different Dressing Materials in Diabetic Foot Ulcers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.V. Hospital for Diabetes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.V. Hospital for Diabetes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of different commonly used&#xD;
      dressings for treating diabetic foot ulcers. It is a prospective study recruiting 50 type 2&#xD;
      diabetic patients with diabetic foot ulcers (2-50cm2). All the patients will give written&#xD;
      informed consent prior to getting enrolled in the study. All the patients will be randomly&#xD;
      assigned to one of the five groups of the study namely, saline (control),Biatin Ag (Foam),&#xD;
      Hydrocolloid, Hydrogel and Ceredak. Follow up of the patients will be done until the complete&#xD;
      healing of the wound takes place. All procedures of dressing will be done by an authorized&#xD;
      and certified Podiatric Surgeon of the Institution. Details on the cost incurred and days&#xD;
      required for the wound to completely heal will be recorded for all the patients.&#xD;
&#xD;
      This study will provide the efficacy of all the dressings used for treating diabetic foot&#xD;
      ulcers and also the cost of each dressing. This will help the surgeons for managing the&#xD;
      diabetic foot ulcers in a better and cost effective way, which in turn will reduce the burden&#xD;
      of patients both physically and financially.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective study aims at determining the efficacy and safety of different dressings&#xD;
      available for treating diabetic foot ulcers. Study has been approved by the Institutional&#xD;
      Ethics Committee before starting. Informed consent will be obtained from all the study&#xD;
      subjects. A total of 50 subjects will be recruited. Study subjects will be divided in five&#xD;
      groups of 10 subjects in each group.All the subjects will be randomly assigned to one of the&#xD;
      study groups namely; Group 1 will the subjects randomized on Normal Saline (Control) and&#xD;
      group 2 will be the subjects randomized on Biatin Ag (Foam) dressing; Group 3 will be&#xD;
      Hydrocolloid, group 4 will be Hydrogel and Group 5 will be Ceredak. Lab investigations&#xD;
      involving glycemic status (HbA1c), lipid profile, renal function test, liver function test&#xD;
      will be done using standard enzymatic procedures. Wound size, colony count and microflora of&#xD;
      the wound will be captured for all the study subjects. Photographs of the wound will be taken&#xD;
      at every follow up visit until the wound is healed. Serum and tissue sample will be collected&#xD;
      for the estimation of pronounced markers like MMP 2 and MMP 9. MMP 2 will be estimated using&#xD;
      ELISA procedure (using standard enzymatic assay kit) and MMP 9 will be estimated using&#xD;
      western blot technique. Histopathology of collagen will be seen using Van Gieson's stain.&#xD;
      Immunohistochemistry will be done for determining collagen IV (marker for basement membrane&#xD;
      thickening) to prove the evident wound healing at a defined point of time. H&amp;E sections will&#xD;
      be taken for determining the inflammation histochemically. All the study subjects will be&#xD;
      followed till the wound healing process is complete. Tissue and serum samples will be&#xD;
      collected for the above mentioned parameters on pre application day, after 1st and 4th week&#xD;
      of the dressing application. A total of 3 visits will be performed for all the study&#xD;
      subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete healing of the wound</measure>
    <time_frame>1 months from the date of application</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Diabetic Foot Ulcers</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>All the subjects in Group 1 will be treated with Normal Saline for healing of their diabetic foot ulcer</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biatin Ag (Foam)</intervention_name>
    <description>All the subjects will be treated with Biatin Ag (Foam)</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Coloplast</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hydrocolloid</intervention_name>
    <description>All the subjects in this group will be treated with Hydrocolloid</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>Coloplast</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hydrogel</intervention_name>
    <description>All the subjects in this group will be treated with Hydrogel</description>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>Coloplast - Purilon Gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ceredak</intervention_name>
    <description>All the subjects in this group will be treated with Micro-porous Ceramic Wound Dressing</description>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with foot ulcers&#xD;
&#xD;
          -  Patients with or without PVD&#xD;
&#xD;
          -  Size of the ulcer: 2-50 cm2&#xD;
&#xD;
          -  Age 30-75 years (both gender)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient having severe infection&#xD;
&#xD;
          -  Size of the foot ulcer &gt; 50cm2&#xD;
&#xD;
          -  Patients not willing to give written informed consent&#xD;
&#xD;
          -  Patient with psychological disorder&#xD;
&#xD;
          -  Patients with severe renal impairment or visual deformity&#xD;
&#xD;
          -  Patients above the age of 75 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vijay Viswanathan, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>DRC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rajesh Kesavan, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>DRC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary Babu, Dr.</last_name>
    <phone>044-25954913</phone>
    <phone_ext>224</phone_ext>
    <email>babumary2000@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vijay Viswanathan, Dr.</last_name>
    <phone>044-25954915</phone>
    <phone_ext>277</phone_ext>
    <email>drvijay@mvdiabetes.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Diabetes Research Centre</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600013</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vijay Viswanathan, Dr</last_name>
      <phone>044-25954915</phone>
      <phone_ext>277</phone_ext>
      <email>drvijay@mvdiabetes.com</email>
    </contact>
    <contact_backup>
      <last_name>Rajesh Kesavan, Dr.</last_name>
      <phone>044-25954913</phone>
      <phone_ext>277</phone_ext>
      <email>dr_vijay@mvdiabetes.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mary Babu, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>April 16, 2010</study_first_submitted>
  <study_first_submitted_qc>April 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2010</study_first_posted>
  <last_update_submitted>April 21, 2012</last_update_submitted>
  <last_update_submitted_qc>April 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>M.V. Hospital for Diabetes</investigator_affiliation>
    <investigator_full_name>Vijay Viswanathan</investigator_full_name>
    <investigator_title>MANAGING DIRECTOR</investigator_title>
  </responsible_party>
  <keyword>Wound healing, type 2 diabetes, diabetic foot ulcers, different dressings</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

